BDX Stock Forecast & Price Target

Becton Dickinson has demonstrated strong revenue growth across its business segments, with the Medical Solutions (MMS) unit reporting sales of $888 million in FQ3'25, reflecting a year-over-year increase of 5.3%, driven by robust demand in Infusion Systems and Dispensing Solutions. The company's MedTech business has consistently achieved over 6% growth annually since the launch of its BD 2025 initiative, showcasing accelerating margins, which reinforces its financial stability. Additionally, the MDS segment reported FY24 sales of $4.43 billion, up 3.2% year-over-year, highlighting the company's ability to maintain growth momentum despite fluctuations in market demand.

Becton Dickinson's recent reaffirmation of its organic revenue growth outlook at 3.0-3.5% y/y reflects a notable reduction from previously issued expectations of 4.0-4.5%. The company's FQ3'25 sales of $1.25 billion represented a decline of 1.1% year-over-year, driven by low-single digit sales decreases in key segments such as Biosciences and Diagnostic Solutions. Additionally, the firm faces significant challenges including volume-based procurement headwinds in China and reduced demand in the Biosciences sector due to government budget cuts and sluggish recovery from past shortages.